Sanofi Looks to Leverage Previous SARS Vaccine Information to Develop COVID-19 Vaccine

March 16, 2020

The following is a response provided by Sanofi. “At Sanofi, we have a simple purpose 鈥 to discover breakthrough medicines and vaccines to improve the lives of millions of people around the world. This drive to transform the practice of medicine has taken on increased urgency for everyone in the Sanofi family since the emergence […]

Bioverativ Data Presented at ASH Underscore Potential for Once Weekly Dosing with Sustained High Factor Levels in Hemophilia A

December 5, 2018

The following is an excerpt from a press release from Bioverativ. Read the press release in its entirety here. Bioverativ Inc.,聽a Sanofi company dedicated to transforming the lives of people with rare blood disorders, presented new data from the EXTEN-A Phase 1/2a trial of BIVV001 showing that a single 65 IU/kg dose of BIVV001 extended […]

Sanofi to Acquire Bioverativ for $11.6 Billion

January 22, 2018

Note:聽The following is edited from a press release from Sanofi. Read the full press release in its entirety聽here. Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 […]

Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance

January 9, 2018

Note:聽The following is edited from a press release from Alnylam. Read the full press release in its entirety聽here. Alnylam Pharmaceuticals, Inc.,聽an RNAi therapeutics company, and Sanofi announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development, and commercialization of certain products for the treatment of rare genetic diseases. Specifically, Alnylam […]

Alnylam & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors

July 10, 2017

Note: The following is an edited version of a press release from Alnylam.聽Read the press release from Alnylam聽in it鈥檚 entirety聽here. Alnylam Pharmaceuticals, Inc. and Sanofi Genzyme,聽announced today new positive results from the ongoing Phase 2 open-label extension study with fitusiran in patients with hemophilia A and B, with or without inhibitors.聽These results were presented today […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.